Skip to main content
. 2021 Nov 14;41:101191. doi: 10.1016/j.eclinm.2021.101191

Table 4.

Clinical and laboratory features and clinical outcome of 501 MERS-CoV patients by gender, Saudi Arabia, 2014-20191

Female Male P-value
Hematology (reference value), median (IQR)
WBC (4.0-11.0) 6.9 (4.6-9.4) 5.7 (3.9-8.8) 0.0143
Hgb (13.5-175) 12.5 (9.9-14.1) 13.9 (11.3-15.3) <0.001
Neutrophil (1.50-7.8) 4.3 (2.7-6.4) 4.0 (2.4 - 6.7) 0.29
Platelets (150-450) 251 (181 - 306) 195 (133-249) <0.001
Blood Chemistry, median (IQR)
Creatinine (62-115) 56 (64-78.8) 77 (67.8 -129.7) <0.001
Albumin (32-46) 33(28-40) 31 (25-37) 0.003
AST(5-34) 39 (24-90) 72.5 (35-118) <0.001
ALT (5-55) 24 (14-53) 43 (24-84) <0.001
Bilirubin (3.4-20.5) 7.7 (5.6-11.3) 10.1 (7-15.6) <0.001
LDH (125-243) 477 (216-603) 546 (375-821) 0.04
Microbiology and culture positive, number of patients (%)
Microbiology test, 44 (35.2) 90 (36.4) 0.81
Blood Culture 26 (18.7) 90 (29.1) 0.02
Urine Culture 25 (18.1) 80 (26.0) 0.07
Respiratory culture 25 (18.0) 84(27.4) 0.03
Other culture 22 (16.1) 88 (29.0) 0.004
Complications, number of patents (%)
Chest x-ray, positive 75 (52.8) 197 (69.1) 0.001
Acute lung Injury 7 (16.7) 24 (16.11) 0.93
Acute renal injury 1 (2.4) 5 (3.4) 0.74
Pneumonia 12 (27.9) 39 (26.2) 0.82
Pleural effusion 2 (4.7) 8 (5.4) 0.88
Cardiac arrest 5 (11.9) 18 (12.2) 0.96
Seizure, stroke, or shock 3 (7.1) 6 (4.1) 0.41
Other 14 (32.3) 14 (29.9) 0.74
No complications 12 (27.9) 59 (38.6) 0.20
Admitted to, number of patients (%)
Intensive care unit 39 (25.2) 130 (37.6) 0.01
Ward 116 (74.8) 216 (62.4) 0.01
Duration of hospital stay, median (IQR)
16 (11-28) 19 (14-30) 0.16
Clinical outcome, number of patients (%)
Died 24 (15.5) 82 (23.7) 0.04
Discharged 124 (80.0) 248 (71.7) 0.05
Transferred 3 (1.9) 8 (2.3) 0.79

1Patients admitted to one of the four MERS-CoV referral hospitals in Saudi Arabia.2Denominator for laboratory and other investigations vary. AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; LDH, lactate dehydrogenase